<DOC>
	<DOC>NCT01214083</DOC>
	<brief_summary>The purpose of this study is to determine whether: (1) the combination of N-acetylcysteine + high-dose naltrexone (150 mg) works better than high-dose naltrexone (150 mg) alone in reducing alcohol drinking; and (2) high-dose naltrexone (150 mg) alone works better than low-dose naltrexone (50 mg) alone in reducing alcohol drinking.</brief_summary>
	<brief_title>N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence</brief_title>
	<detailed_description>The 3 groups (N-acetylcysteine plus naltrexone 150 mg, naltrexone 150 mg, and naltrexone 50 mg) will be compared in a 12-week randomized, double-blind clinical trial.</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>age 1865 years alcohol dependence by DSMIV criteria heavy drinking at least 6 times within the past month ('heavy drinking' defined as 5 or more standard drinks per day for men and 4 or more standard drinks for women) able to provide informed consent a score of 6 or more on the Penn Alcohol Craving Scale (PACS) subject agrees not to take overthecounter analgesics during the study current drug abuse or dependence by DSMIV criteria (except nicotine and marijuana) current psychotic disorders or bipolar disorders current suicidal or homicidal ideation positive illicit drug screen test (except marijuana) ongoing narcotic use or risks for narcotic use during the study increased risk for severe alcohol withdrawal by a score of 10 or more on the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWAAr) clinically significant cardiac, hepatic, renal, neurologic, or pulmonary disease baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times normal current use of disulfiram, acamprosate or topiramate pregnant or nursing, or inadequate birth control methods in women of childbearing potential alcohol breathalyzer level 0.08 or more at the screening visit severe alcohol withdrawal (delirium tremens or withdrawal seizures) within the past year currently requiring inpatient treatment for treating alcohol dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>N-acetylcysteine</keyword>
	<keyword>naltrexone</keyword>
</DOC>